logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Promising results with osimertinib for EGFR-NSCLC with LMs

Phase 1 trial finds good objective response rates and PFS in EGFR-mutated NSCLC with leptomeningeal metastases.